
Acorda Therapeutics, Inc - Strategy, SWOT and Corporate Finance Report
Description
Acorda Therapeutics, Inc - Strategy, SWOT and Corporate Finance Report
Summary
Acorda Therapeutics, Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.
Key Highlights
Acorda Therapeutics, Inc. (Acorda or 'the company') is engaged in the identification, development and commercialization of novel therapies to treat neurological disorders. It is also engaged in the development and marketing of therapies to help restore function in persons with spinal cord injury, multiple sclerosis and related conditions of the central nervous system. The company also offers various pipeline products to neurological therapies including heart failure, migraine, Primary Sclerosing Cholangitis, MS, spinal cord injury and various other disorders. Acorda's product portfolio are marketed under Zanaflex, Ampyra or Fampyra (dalfampridine); Inbrija, BTT1023, and GGF2. It develops additional inhaled medicines for both systemic and pulmonary conditions. Acorda primarily operates in the US. The company is headquartered in Ardsley, New York, the US
Scope
Summary
Acorda Therapeutics, Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.
Key Highlights
Acorda Therapeutics, Inc. (Acorda or 'the company') is engaged in the identification, development and commercialization of novel therapies to treat neurological disorders. It is also engaged in the development and marketing of therapies to help restore function in persons with spinal cord injury, multiple sclerosis and related conditions of the central nervous system. The company also offers various pipeline products to neurological therapies including heart failure, migraine, Primary Sclerosing Cholangitis, MS, spinal cord injury and various other disorders. Acorda's product portfolio are marketed under Zanaflex, Ampyra or Fampyra (dalfampridine); Inbrija, BTT1023, and GGF2. It develops additional inhaled medicines for both systemic and pulmonary conditions. Acorda primarily operates in the US. The company is headquartered in Ardsley, New York, the US
Scope
- Detailed information on Acorda Therapeutics, Inc required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Acorda Therapeutics, Inc in the form of a SWOT analysis
- An in-depth view of the business model of Acorda Therapeutics, Inc including a breakdown and examination of key business segments
- Intelligence on Acorda Therapeutics, Inc's mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Acorda Therapeutics, Inc, such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends
- Gain understanding of Acorda Therapeutics, Inc and the factors that influence its strategies.
- Track strategic initiatives of the company and latest corporate news and actions.
- Assess Acorda Therapeutics, Inc as a prospective partner, vendor or supplier.
- Support sales activities by understanding your customers' businesses better.
- Stay up to date on Acorda Therapeutics, Inc's business structure, strategy and prospects.
Table of Contents
50 Pages
- Company Snapshot
- Acorda Therapeutics, Inc.: Company Overview
- Acorda Therapeutics, Inc.: Overview and Key Facts
- Acorda Therapeutics, Inc.: Overview
- Acorda Therapeutics, Inc.: Key Facts
- Acorda Therapeutics, Inc.: Key Employees
- Acorda Therapeutics, Inc.: Key Employee Biographies
- Acorda Therapeutics, Inc.: Major Products and Services
- Acorda Therapeutics, Inc.: Company History
- Acorda Therapeutics, Inc.: Management Statement
- Acorda Therapeutics, Inc.: Locations and Subsidiaries
- Acorda Therapeutics, Inc.: Key Competitors
- Acorda Therapeutics, Inc.: Company Analysis
- Acorda Therapeutics, Inc.: Business Description
- Acorda Therapeutics, Inc.: SWOT Analysis
- Acorda Therapeutics, Inc.: SWOT Overview
- Acorda Therapeutics, Inc.: Strengths
- Acorda Therapeutics, Inc.: Weaknesses
- Acorda Therapeutics, Inc.: Opportunities
- Acorda Therapeutics, Inc.: Threats
- Acorda Therapeutics, Inc.: Corporate Financial Deals Activity
- Acorda Therapeutics, Inc.: Financial Deals Overview
- Acorda Therapeutics, Inc.: Targets and Partners
- Acorda Therapeutics, Inc.: Top Deals 2018 - 2022YTD*
- Acorda Therapeutics, Inc.: Advisors
- Acorda Therapeutics, Inc.: Top Legal Advisors
- Acorda Therapeutics, Inc.: Top Financial Advisors
- Acorda Therapeutics, Inc.: Capital Raising
- Acorda Therapeutics, Inc.: Partnership
- Acorda Therapeutics, Inc.: Divestments
- Acorda Therapeutics, Inc.: Recent Developments
- Acorda Therapeutics, Inc.: News and Events Summary
- Acorda Therapeutics, Inc.: Contracts
- Acorda Therapeutics, Inc.: Corporate Governance
- Acorda Therapeutics, Inc.: Financial Deals
- Acorda Therapeutics, Inc.: Financial Performance
- Acorda Therapeutics, Inc.: Strategy and Operations
- Appendix
- Contact Us
- Methodology
- About MarketLine
- List of Tables
- Table 1: Acorda Therapeutics, Inc.: Key Facts
- Table 2: Acorda Therapeutics, Inc.: Key Employees
- Table 3: Acorda Therapeutics, Inc.: Company History
- Table 4: Acorda Therapeutics, Inc.: Locations and Subsidiaries
- Table 5: Acorda Therapeutics, Inc.: Key Competitors
- Table 6: Acorda Therapeutics, Inc.: Deal Activity by Deal Type - Volume (TTM*)
- Table 7: Acorda Therapeutics, Inc.: Deal Activity by Deal Type - Volume (2018 - YTD*2022)
- Table 8: Acorda Therapeutics, Inc.: Targets and Partners
- Table 9: Acorda Therapeutics, Inc.: Top Deals 2018 - 2022YTD*
- Table 10: Acorda Therapeutics, Inc.: Legal Advisor Ranking by Value (US$m)
- Table 11: Acorda Therapeutics, Inc.: Financial Advisor Ranking by Value (US$m)
- Table 12: Acorda Therapeutics, Inc.: Capital Raising Volume and Value Trend (2018 - YTD*2022)
- Table 13: Acorda Therapeutics, Inc.: Capital Raising by Deal Type (2018 - YTD*2022)
- Table 14: Acorda Therapeutics, Inc.: Partnership Volume and Value Trend (2018 - YTD*2022)
- Table 15: Acorda Therapeutics, Inc.: Partnership Trend by Deal Type (2018 - YTD*2022)
- Table 16: Acorda Therapeutics, Inc.: Divestments Volume and Value Trend (2018 - YTD*2022)
- Table 17: Acorda Therapeutics, Inc.: News and Events Summary
- Table 18: Acorda Therapeutics, Inc.: Contracts
- Table 19: Acorda Therapeutics, Inc.: Corporate Governance
- Table 20: Acorda Therapeutics, Inc.: Financial Deals
- Table 21: Acorda Therapeutics, Inc.: Financial Performance
- Table 22: Acorda Therapeutics, Inc.: Strategy and Operations
- List of Figures
- Figure 1: Acorda Therapeutics, Inc.: Deal Activity by Deal Type - Volume (TTM*)
- Figure 2: Acorda Therapeutics, Inc.: Deal Activity by Deal Type - Volume (2018 - YTD*2022)
- Figure 3: Acorda Therapeutics, Inc.: Capital Raising Volume and Value Trend (2018 - YTD*2022)
- Figure 4: Acorda Therapeutics, Inc.: Capital Raising by Deal Type (2018 - YTD*2022)
- Figure 5: Acorda Therapeutics, Inc.: Partnership Volume and Value Trend (2018 - YTD*2022)
- Figure 6: Acorda Therapeutics, Inc.: Partnership Trend by Deal Type (2018 - YTD*2022)
- Figure 7: Acorda Therapeutics, Inc.: Divestments Volume and Value Trend (2018 - YTD*2022)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.